title: Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders.
abstract: Stimulant use disorder is an important public health problem, with an estimated 2.1 million current users in the United States alone. No pharmacological treatments are approved by the U.S. Food and Drug Administration for stimulant use disorder and behavioral treatments have variable efficacy and limited availability. Most individuals with stimulant use disorder have other comorbidities, most with overlapping symptoms and cognitive impairments. The goal of this article is to present a rationale for cognition as a treatment target in stimulant use disorder and to outline potential treatment approaches. Rates of lifetime comorbid psychiatric disorders among people with stimulant use disorders are estimated at 65% to 73%, with the most common being mood disorders (13% to 64%) and anxiety disorders (21% to 50%), as well as non-substance-induced psychotic disorders (<10%). There are several models of addictive behavior, but the dual process model particularly highlights the relevance of cognitive impairments and biases to the development and maintenance of addiction. This model explains addictive behavior as a balance between automatic processes and executive control, which in turn are related to individual (genetics, comorbid disorders, psychosocial factors) and other (craving, triggers, drug use) factors. Certain cognitive impairments, such as attentional bias and approach bias, are most relevant to automatic processes, while sustained attention, response inhibition, and working memory are primarily related to executive control. These cognitive impairments and biases are also common in disorders frequently comorbid with stimulant use disorder and predict poor treatment retention and clinical outcomes. As such, they may serve as feasible transdiagnostic treatment targets. There are promising pharmacological, cognitive, and behavioral approaches that aim to enhance cognitive function. Pharmacotherapies target cognitive impairments associated with executive control and include cholinesterase inhibitors (e.g., galantamine, rivastigmine) and monoamine transporter inhibitors (e.g., modafinil, methylphenidate). Cognitive behavioral therapy and cognitive rehabilitation also enhance executive control, while cognitive bias modification targets impairments associated with automatic processes. Cognitive enhancement to improve treatment outcomes is a novel and promising strategy, but its clinical value for the treatment of stimulant use disorder, with or without other psychiatric comorbidities, remains to be determined in future studies.
authors.affiliation: a Department of Psychiatry , Yale University School of Medicine , West Haven , Connecticut , USA.|b VA Connecticut Healthcare System , West Haven , Connecticut , USA.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Sofuoglu
authors.affiliation: a Department of Psychiatry , Yale University School of Medicine , West Haven , Connecticut , USA.|b VA Connecticut Healthcare System , West Haven , Connecticut , USA.
authors.forename: Elise E
authors.initials: EE
authors.lastname: DeVito
authors.affiliation: c Department of Medical and Clinical Psychology , Uniformed Services University of the Health Science , Bethesda , Maryland , USA.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Waters
authors.affiliation: a Department of Psychiatry , Yale University School of Medicine , West Haven , Connecticut , USA.|b VA Connecticut Healthcare System , West Haven , Connecticut , USA.
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Carroll
mesh_terms: D003071:Cognition; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D017831:Diagnosis, Dual (Psychiatry); D006801:Humans; D001523:Mental Disorders / Q000150:complications* / Q000523:psychology / Q000628:therapy*; D008960:Models, Psychological; D018697:Nootropic Agents / Q000627:therapeutic use*; D019966:Substance-Related Disorders / Q000150:complications* / Q000523:psychology / Q000628:therapy*
chemical_list: D018697:Nootropic Agents
keywords: Attentional retraining; cocaine; cognitive behavioral therapy; cognitive bias modification; cognitive enhancement; cognitive remediation; methamphetamine; pharmacotherapy; psychotherapy
references.citation: Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16667-72
references.pmid: 20823246
references.citation: Pharmacol Biochem Behav. 2011 Aug;99(2):130-45
references.pmid: 21463652
references.citation: Behav Res Ther. 2014 Dec;63:25-35
references.pmid: 25277496
references.citation: J Clin Exp Neuropsychol. 2005 Feb;27(2):189-204
references.pmid: 15903150
references.citation: Arch Clin Neuropsychol. 2005 Aug;20(6):727-44
references.pmid: 15953706
references.citation: J Exp Psychol. 1980 Jun;109(2):160-74
references.pmid: 7381367
references.citation: Addict Biol. 2009 Jan;14(1):22-31
references.pmid: 18855805
references.citation: Psychiatry Res. 2011 Apr 30;186(2-3):356-61
references.pmid: 21055832
references.citation: Neuropharmacology. 2013 Jan;64:472-8
references.pmid: 22796108
references.citation: J Neurosci. 2001 Dec 1;21(23):9414-8
references.pmid: 11717374
references.citation: Brain Inj. 2014;28(12):1610-6
references.pmid: 25058353
references.citation: J Clin Psychiatry. 2006 Feb;67(2):247-57
references.pmid: 16566620
references.citation: Clin Neuropharmacol. 2009 Mar-Apr;32(2):63-8
references.pmid: 18978490
references.citation: J Clin Psychol. 2014 Dec;70(12):1133-57
references.pmid: 24652823
references.citation: Psychopharmacology (Berl). 2009 Jan;202(1-3):531-9
references.pmid: 18818905
references.citation: Cognit Ther Res. 2012 Oct 1;36(5):427-440
references.pmid: 23459093
references.citation: JAMA. 2004 Apr 21;291(15):1887-96
references.pmid: 15100209
references.citation: Neurosci Biobehav Rev. 2009 May;33(5):631-46
references.pmid: 18835296
references.citation: Neuropsychopharmacology. 2008 Mar;33(4):827-36
references.pmid: 17568399
references.citation: Schizophr Res. 2013 Oct;150(1):42-50
references.pmid: 23911259
references.citation: J Neurosci. 2013 May 15;33(20):8742-52
references.pmid: 23678117
references.citation: Schizophr Res. 2013 Oct;150(1):289-96
references.pmid: 23938173
references.citation: J Addict Dis. 2015;34(1):88-100
references.pmid: 25415384
references.citation: Cogn Affect Behav Neurosci. 2010 Mar;10(1):8-20
references.pmid: 20233952
references.citation: CNS Drugs. 2009 Nov;23(11):939-52
references.pmid: 19845415
references.citation: Science. 2012 Feb 3;335(6068):601-4
references.pmid: 22301321
references.citation: ACS Chem Neurosci. 2015 Apr 15;6(4):522-5
references.pmid: 25734247
references.citation: Am J Drug Alcohol Abuse. 2007;33(2):191-206
references.pmid: 17497542
references.citation: Behav Res Ther. 1998 Sep;36(9):809-48
references.pmid: 9701859
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):141-6
references.pmid: 22230648
references.citation: Subst Abuse Rehabil. 2015 Jun 17;6:61-74
references.pmid: 26124696
references.citation: Schizophr Res. 2006 Jul;85(1-3):73-83
references.pmid: 16797163
references.citation: PLoS One. 2015;10(6):e0127955
references.pmid: 26070195
references.citation: Neuropsychopharmacology. 2006 Sep;31(9):2055-64
references.pmid: 16482089
references.citation: Neuroscience. 2015 Nov 19;309:200-13
references.pmid: 25934030
references.citation: CNS Spectr. 2014 Jun;19(3):215-24
references.pmid: 24642267
references.citation: Arch Gen Psychiatry. 1991 Jan;48(1):43-51
references.pmid: 1984761
references.citation: Psychol Bull. 2015 Jan;141(1):105-40
references.pmid: 25365762
references.citation: Arch Gen Psychiatry. 2006 Mar;63(3):324-31
references.pmid: 16520439
references.citation: Psychol Sci. 2011 Apr;22(4):490-7
references.pmid: 21389338
references.citation: Neuropsychol Rev. 2007 Sep;17(3):275-97
references.pmid: 17694436
references.citation: Nat Rev Drug Discov. 2012 Feb;11(2):141-68
references.pmid: 22293568
references.citation: BMC Psychiatry. 2012;12:64
references.pmid: 22715980
references.citation: Biol Psychiatry. 2008 Oct 1;64(7):636-9
references.pmid: 18504036
references.citation: Drug Alcohol Depend. 2007 Feb 23;87(1):20-9
references.pmid: 16930863
references.citation: Biol Psychiatry. 2011 Feb 1;69(3):260-5
references.pmid: 20965498
references.citation: Psychopharmacology (Berl). 2013 Oct;229(3):415-34
references.pmid: 23934211
references.citation: Biol Psychiatry. 2010 Dec 1;68(11):982-90
references.pmid: 20887977
references.citation: Psychol Bull. 2009 Jul;135(4):589-607
references.pmid: 19586163
references.citation: J Subst Abuse. 1993;5(2):117-30
references.pmid: 8400835
references.citation: Subst Abuse. 2009 Aug 26;1:63-79
references.pmid: 19898674
references.citation: Psychiatry Res. 2013 Nov 30;214(2):142-52
references.pmid: 23993991
references.citation: Exp Clin Psychopharmacol. 2011 Feb;19(1):11-9
references.pmid: 21341919
references.citation: Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14931-6
references.pmid: 16192352
references.citation: J Abnorm Psychol. 2002 Feb;111(1):107-23
references.pmid: 11866165
references.citation: Exp Clin Psychopharmacol. 2014 Dec;22(6):469-83
references.pmid: 25222545
references.citation: Addiction. 2002 Jul;97(7):861-9
references.pmid: 12133125
references.citation: Schizophr Bull. 2011 Nov;37(6):1318-26
references.pmid: 20547571
references.citation: Acta Psychiatr Scand. 2013 Sep;128(3):149-62
references.pmid: 23617548
references.citation: J Exp Psychol Gen. 2008 May;137(2):201-25
references.pmid: 18473654
references.citation: Schizophr Res. 2015 Oct;168(1-2):213-22
references.pmid: 26305063
references.citation: J Nerv Ment Dis. 1993 Feb;181(2):71-9
references.pmid: 8426174
references.citation: Drug Alcohol Depend. 2012 Jan 1;120(1-3):135-41
references.pmid: 21840138
references.citation: Psychiatry Res. 2012 Dec 30;200(2-3):734-41
references.pmid: 22910475
references.citation: Drug Alcohol Depend. 2012 Apr 1;122(1-2):142-8
references.pmid: 22018602
references.citation: Am J Psychiatry. 2011 May;168(5):472-85
references.pmid: 21406461
references.citation: Psychol Addict Behav. 2006 Sep;20(3):241-53
references.pmid: 16938062
references.citation: J Subst Abuse Treat. 2012 Oct;43(3):303-12
references.pmid: 22377391
references.citation: Biol Psychiatry. 2008 Dec 1;64(11):998-1004
references.pmid: 18635157
references.citation: Am J Psychiatry. 2008 Feb;165(2):203-13
references.pmid: 18172019
references.citation: Am J Drug Alcohol Abuse. 2009;35(1):12-7
references.pmid: 19152200
references.citation: Exp Clin Psychopharmacol. 2010 Apr;18(2):109-19
references.pmid: 20384422
references.citation: Psychopharmacology (Berl). 2008 Aug;199(3):439-56
references.pmid: 18542931
references.citation: Neuropsychopharmacology. 2011 Apr;36(5):950-9
references.pmid: 21289606
references.citation: Psychopharmacology (Berl). 2005 Mar;178(2-3):286-95
references.pmid: 15338103
references.citation: Neuropsychopharmacology. 2005 Jan;30(1):205-11
references.pmid: 15525998
references.citation: Ann N Y Acad Sci. 2011 Jan;1216:73-85
references.pmid: 21272012
references.citation: J Subst Abuse Treat. 2009 Dec;37(4):328-34
references.pmid: 19394790
references.citation: Am J Psychiatry. 2008 Feb;165(2):179-87
references.pmid: 18198270
references.citation: Pharmacol Ther. 2015 Sep;153:135-47
references.pmid: 26116809
references.citation: Addiction. 2008 Nov;103(11):1875-82
references.pmid: 19032536
references.citation: Am J Psychiatry. 2008 Jan;165(1):82-9
references.pmid: 17986678
references.citation: Drug Alcohol Depend. 2009 Nov 1;105(1-2):48-55
references.pmid: 19608354
references.citation: Physiol Behav. 2011 Jul 25;104(1):76-81
references.pmid: 21549724
references.citation: Behav Ther. 2012 Dec;43(4):724-40
references.pmid: 23046776
references.citation: Schizophr Bull. 2010 Jan;36(1):36-42
references.pmid: 19776206
references.citation: Am J Psychiatry. 2014 Apr;171(4):436-44
references.pmid: 24577287
references.citation: J Nerv Ment Dis. 2013 Aug;201(8):680-5
references.pmid: 23896849
references.citation: Br J Psychiatry. 2015 Jan;206(1):7-16
references.pmid: 25561486
references.citation: Prog Neurobiol. 2005 Apr;75(6):406-33
references.pmid: 15955613
references.citation: Biol Psychiatry. 2013 May 15;73(10):1015-23
references.pmid: 23452665
references.citation: Pharmacol Rev. 2015 Jul;67(3):681-96
references.pmid: 26106146
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:137-42
references.pmid: 24239594
references.citation: J Stud Alcohol Drugs. 2010 May;71(3):335-44
references.pmid: 20409426
references.citation: Psychol Bull. 2014 May;140(3):682-721
references.pmid: 24188418
references.citation: J Clin Psychiatry. 2013 Nov;74(11):1101-7
references.pmid: 24330897
references.citation: Am J Addict. 2011 May-Jun;20(3):302-3
references.pmid: 21477060
references.citation: Schizophr Res. 2013 Aug;148(1-3):138-44
references.pmid: 23768813
references.citation: Curr Addict Rep. 2014 Dec 1;1(4):243-250
references.pmid: 25530935
references.citation: Eur Neuropsychopharmacol. 2014 Jan;24(1):5-50
references.pmid: 24176673
references.citation: BMC Med. 2013;11:126
references.pmid: 23672542
references.citation: Psychol Bull. 2011 Nov;137(6):940-58
references.pmid: 21728399
references.citation: Am J Addict. 2010 Jul-Aug;19(4):340-4
references.pmid: 20653641
references.citation: Exp Clin Psychopharmacol. 2010 Dec;18(6):489-97
references.pmid: 21186923
references.citation: Int J Methods Psychiatr Res. 2014 Jan;23 Suppl 1:41-57
references.pmid: 24375535
references.citation: Drug Alcohol Rev. 2013 Jan;32(1):88-95
references.pmid: 22630616
references.citation: Addiction. 2010 Jan;105(1):38-48
references.pmid: 20078461
references.citation: Drug Alcohol Depend. 2009 Sep 1;104(1-2):133-9
references.pmid: 19560290
references.citation: Drug Alcohol Depend. 2010 Jun 1;109(1-3):30-6
references.pmid: 20064698
references.citation: Eur J Neurosci. 2014 Jun;39(11):1912-20
references.pmid: 24593677
references.citation: Health Psychol. 2014 Oct;33(10):1232-40
references.pmid: 24818609
references.citation: Schizophr Res. 2010 Jun;119(1-3):246-52
references.pmid: 20399613
references.citation: Can J Psychiatry. 2013 Jun;58(6):319-25
references.pmid: 23768259
references.citation: Addict Biol. 2013 Mar;18(2):203-13
references.pmid: 22264351
references.citation: Drug Alcohol Depend. 2003 Aug 20;71(2):207-11
references.pmid: 12927659
references.citation: J Affect Disord. 2011 Nov;134(1-3):20-31
references.pmid: 21163534
references.citation: Arch Gen Psychiatry. 2011 Sep;68(9):942-52
references.pmid: 21536969
references.citation: Schizophr Res. 2008 Jul;102(1-3):88-95
references.pmid: 18325740
references.citation: Neuropharmacology. 2013 Jan;64:452-63
references.pmid: 22735770
references.citation: Am J Psychiatry. 2014 May;171(5):510-22
references.pmid: 24700194
references.citation: Schizophr Res. 2011 Feb;125(2-3):267-77
references.pmid: 20850275
references.citation: Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14455-9
references.pmid: 20660731
references.citation: Schizophr Bull. 2005 Jan;31(1):5-19
references.pmid: 15888422
references.citation: Philos Trans R Soc Lond B Biol Sci. 1998 Nov 29;353(1377):1915-27
references.pmid: 9854264
references.citation: Eur Neuropsychopharmacol. 2012 Jan;22(1):1-16
references.pmid: 21723712
references.citation: Psychol Med. 2014 Jul;44(10):2029-40
references.pmid: 24168753
references.citation: Addict Biol. 2013 Jul;18(4):752-61
references.pmid: 22339903
references.citation: Neuropsychol Rev. 2013 Mar;23(1):27-47
references.pmid: 23412885
references.citation: Psychiatr Clin North Am. 1999 Jun;22(2):351-70
references.pmid: 10385938
references.citation: J Addict Med. 2014 Sep-Oct;8(5):368-76
references.pmid: 25187977
references.citation: Br J Clin Pharmacol. 2014 Feb;77(2):382-400
references.pmid: 23039267
references.citation: Biol Psychiatry. 2006 Sep 15;60(6):530-3
references.pmid: 16806095
references.citation: Drug Alcohol Depend. 2008 Sep 1;97(1-2):1-20
references.pmid: 18479844